AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
Phase 2
Terminated
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: Short acting beta agonist (SABA) (rescue medication)Drug: Run-in medications (ICS-LABA combination)
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT04643158
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study of AZD8233 in Participants With Dyslipidemia
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 119
- Registration Number
- NCT04641299
- Locations
- 🇸🇰
Research Site, Trebišov, Slovakia
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Phase 2
Active, not recruiting
- Conditions
- Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT04639219
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT04630067
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
Phase 1
Completed
- Conditions
- Advanced Haematological Malignancies
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04630756
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
Phase 2
Completed
- Conditions
- Chronic BronchitisChronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT04631016
- Locations
- 🇬🇧
Research Site, Newcastle-Upon-Tyne, United Kingdom
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5197
- Registration Number
- NCT04625725
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1131
- Registration Number
- NCT04625972
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 371
- Registration Number
- NCT04612751
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Biological: MEDI9253Biological: Durvalumab
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04613492
- Locations
- 🇫🇷
Research Site, Villejuif, France
© Copyright 2025. All Rights Reserved by MedPath